EGFR and non-small cell lung carcinoma: The most common EGFR mutations associated with sensitivity to tyrosine kinase inhibitors include the deletion of exon 19 (approximately 45% of patients with EGFR mutations) and the L858R mutation in exon 21 (approximately 40%) in NSCLC (61).